<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124841">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477320</url>
  </required_header>
  <id_info>
    <org_study_id>11.0170</org_study_id>
    <nct_id>NCT01477320</nct_id>
  </id_info>
  <brief_title>Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.</brief_title>
  <official_title>Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. Prospective, Double-blind, Randomized, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Saad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      study is to determine if proton pump inhibitors plus enteral nutrition is superior to
      enteral nutrition alone as a stress ulcer prophylaxis strategy in critically ill patients in
      terms of incidence of overt and significant GI bleeding related to stress gastropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI bleeding</measure>
    <time_frame>Time to event :Subjects will be followed from date of randomization until discharge from the ICU or cessation of Enteral Nutrition (EN) and successful initiation of oral feeds</time_frame>
    <description>Incidence of overt GI bleeding (as defined by the presence of coffee ground emesis, hematemesis of bright red blood, melena, or hematochezia) seen with Proton Pump Inhibitor (PPI) and EN versus EN alone in critically ill patients.
Incidence of significant GI bleeding, defined by a 3-point decrease in hematocrit within 24 hours accompanied by signs of overt GI bleeding, or by an unexplained 6-point decrease in hematocrit during any 48 hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Cost to the pharmacy for care related to stress ulcer prophylaxis and treatment of GI bleeding. 2.Incidence of ICU-acquired C. Difficile pseudomembranous colitis.</measure>
    <time_frame>Time to event: Subjects will be followed until discharge from the ICU or cessation of EN and successful initiation of oral feeds.</time_frame>
    <description>Cost to the pharmacy for care related to stress ulcer prophylaxis and treatment of GI bleeding (overt or significant) for patients receiving a PPI agent plus EN versus patients placed on EN alone.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Gastrointestinal Hemorrhage</condition>
  <condition>Clostridium Difficile Colitis</condition>
  <arm_group>
    <arm_group_label>Pantoprazole 40mg IV daily and tube feed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and tube feed.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40 mg IV daily and tube feed.</intervention_name>
    <description>Patients randomized to the control group &quot;active Comparator&quot; will receive tube feed plus an Pantoprazole 40 mg IV daily.</description>
    <arm_group_label>Pantoprazole 40mg IV daily and tube feed</arm_group_label>
    <other_name>Tube feed formula:(Vital AF 1.2 Cal(TM),Abbott,Columbus,OH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo and tube feed</intervention_name>
    <description>Patients randomized to Placebo group &quot;placebo Comparator&quot; will receive tube feed plus an Placebo.</description>
    <arm_group_label>Placebo and tube feed.</arm_group_label>
    <other_name>Tube feed formula:(Vital AF 1.2 Cal(TM),Abbott,Columbus,OH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Admission to the medical ICU at University of Louisville Hospital or Jewish Hospital

          -  Expected need for mechanical ventilation &gt; 48 hours

          -  No contraindication to EN within the first 24 hours after admission to the ICU

        Exclusion Criteria:

          -  Evidence of active GI bleeding during current hospitalization prior to study entry

          -  Admission to ICU with primary diagnosis of burn injury

          -  Closed head injury or increased intracranial pressure

          -  Partial or complete gastrectomy

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Saad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 26, 2017</lastchanged_date>
  <firstreceived_date>October 4, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Mohamed Saad</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Stress Ulcer Prophylaxis</keyword>
  <keyword>Critically Ill Patients</keyword>
  <keyword>Overt and significant GI bleeding</keyword>
  <keyword>Stress gastropathy</keyword>
  <keyword>Clostridium Difficile pseudomembranous colitis</keyword>
  <keyword>Vital AF</keyword>
  <keyword>Small peptide fish oil structured lipids</keyword>
  <keyword>Fructose oligosaccharide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
